PMID- 23927488
OWN - NLM
STAT- MEDLINE
DCOM- 20140415
LR  - 20130923
IS  - 1532-2513 (Electronic)
IS  - 0892-3973 (Linking)
VI  - 35
IP  - 5
DP  - 2013 Oct
TI  - Suppression of phagosome proteolysis and Matrigel migration with the 
      alpha2-adrenergic receptor agonist dexmedetomidine in murine dendritic cells.
PG  - 558-66
LID - 10.3109/08923973.2013.822509 [doi]
AB  - Dexmedetomidine is a highly-selective alpha2-adrenergic receptor agonist used for 
      sedation of critically ill patients in an intensive care setting. Dendritic cells 
      (DCs) in peripheral tissues sense certain foreign antigens and ingest and process 
      them, while migrating to the regional lymph node. Then, DCs present the processed 
      antigen on their surface to stimulate the clonal proliferation of cognitive 
      lymphocytes, leading to the establishment of adaptive immunity. In murine bone 
      marrow-derived DCs, dexmedetomidine significantly delayed the intracellular 
      proteolytic degradation of ovalbumin, while it did not affect phagocytosis, 
      decreased the expression of the surface molecules I-A(b) and CD86, and suppressed 
      cognitive helper T-cell proliferation. Furthermore, dexmedetomidine significantly 
      suppressed DC migration both in vitro, using a Matrigel migration assay, and in 
      vivo, using a foot pad-popliteal lymph node migration assay, which may be 
      ascribed to the inhibition of type IV collagenase/gelatinase activity. Finally, 
      vaccination with dexmedetomidine-treated DCs significantly suppressed the contact 
      hypersensitivity reaction in vivo. These results indicate that dexmedetomidine 
      may suppress immunity by inhibiting DC antigen processing/presentation and 
      migration.
FAU - Ueshima, Hironobu
AU  - Ueshima H
AD  - Department of Anesthesiology, Kansai Medical University , Osaka , Japan.
FAU - Inada, Takefumi
AU  - Inada T
FAU - Shingu, Koh
AU  - Shingu K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130808
PL  - England
TA  - Immunopharmacol Immunotoxicol
JT  - Immunopharmacology and immunotoxicology
JID - 8800150
RN  - 0 (Adrenergic alpha-2 Receptor Agonists)
RN  - 0 (Drug Combinations)
RN  - 0 (Laminin)
RN  - 0 (Proteoglycans)
RN  - 119978-18-6 (matrigel)
RN  - 67VB76HONO (Dexmedetomidine)
RN  - 9007-34-5 (Collagen)
SB  - IM
MH  - Adoptive Transfer
MH  - Adrenergic alpha-2 Receptor Agonists/*pharmacology
MH  - Animals
MH  - Antigen Presentation/drug effects/immunology
MH  - Cell Movement/*drug effects/immunology
MH  - Collagen/chemistry
MH  - Dendritic Cells/cytology/enzymology/*immunology
MH  - Dermatitis, Contact/enzymology/immunology/therapy
MH  - Dexmedetomidine/*pharmacology
MH  - Drug Combinations
MH  - Laminin/chemistry
MH  - Male
MH  - Mice
MH  - Phagosomes/*immunology/metabolism
MH  - Proteoglycans/chemistry
MH  - Proteolysis/*drug effects
MH  - Vaccination
EDAT- 2013/08/10 06:00
MHDA- 2014/04/16 06:00
CRDT- 2013/08/10 06:00
PHST- 2013/08/10 06:00 [entrez]
PHST- 2013/08/10 06:00 [pubmed]
PHST- 2014/04/16 06:00 [medline]
AID - 10.3109/08923973.2013.822509 [doi]
PST - ppublish
SO  - Immunopharmacol Immunotoxicol. 2013 Oct;35(5):558-66. doi: 
      10.3109/08923973.2013.822509. Epub 2013 Aug 8.